Volume 22 Issue 4, April 2004
News in Brief
Throwing money at biodefense
US funding for biodefense research continues on an upward trend, but some say the effort is misguided. Laura DeFrancesco reports.
Making prevention pay
Funding for biodefense is spurring new vaccine and anti-infective programs at several biotech companies.
News & Views
Profiling epithelial stem cells
Two reports shed light on the gene expression patterns of hair follicle stem cells.
Finding needles in haystacks
Probes that reversibly recognize oligohistidine sequences engineered into proteins can provide insights into the structure and location of proteins in living cells.
Unshackling expression profiling arrays
Two enzymes, a microtiter plate and a hexamer oligonucleotide chip decouple microarrays from specific biological systems.
Either/or selection markers for plant transformation
The use of D-amino acid oxidase as a marker gene allows positive or negative selection of plants that have incorporated transgenic DNA.
On the road to therapeutic cloning
Human embryonic stem (ES) cells have been derived from cloned embryos, an important step in the development of therapeutic cloning.
US courts struggle with new patent infringement standards
The lesson from Festo is that during patent prosecution, what you say (or don't say) and what you do (or don't do) will be used against you.
New on the Market
Careers and Recruitment
Too little, too late: when is the right time for new leadership in biotech?
Managers unable to cope with their company's growth and other changes can engender value-destroying delays—and even the company's failure.